Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Seven Corners Capital Management, LLC Scott Klarquist | “Merrimack Pharmaceuticals represents an uncorrelated CVR event play with substantial tax-sheltered cash potential. FDA approval of Onivyde triggers a $225 million payment from Ipsen worth roughly $17 per share, supported by heavy insider buying.” | BULL | Q4 2023 Dec 31, 2023 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
